The objective of this randomized phase III open label trial is to assess if upfront
combination of enzalutamide and Ra223 improves radiological progression-free survival
compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration
resistant prostate cancer patients metastatic to bone.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
Academic and Community Cancer Research United Astellas Pharma Europe Ltd. Bayer Canadian Urologic Oncology Group Cancer Trials Ireland UNICANCER